Not enough data
Martin David Harp's coverage predominantly focuses on ophthalmology, eye care, and FDA approvals within the healthcare and pharmaceutical industry. His articles often cite data and include press releases or announcements from relevant companies or organizations in this field.
Based on his focus, Martin would likely value pitches that offer insights into groundbreaking medical advances in ophthalmology, particularly those related to new treatments, technologies, or FDA approvals. Given the emphasis on citing data and expert commentary in his coverage attributes, he may be receptive to pitches featuring credible experts who can provide insightful analysis of the latest developments in these areas.
As a journalist with a national focus on Australia but covering international topics such as COVID-19 impact on ophthalmology education in the UK, it could be beneficial to tailor pitches by highlighting any relevance or implications for the Australian context when applicable.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Martin David Harp, Hasenin Al-Khersan Md, Kassi Filkins
Hasenin Al-khersan, MD, of the Retina Group of Florida, shares real-world RCA registry findings showing that pegcetacoplan significantly reduced both photoreceptor and RPE loss in eyes with GA.
By: Martin David Harp
Glaukos finishes US pivotal enrollment for Preserflo MicroShunt, targeting advanced glaucoma after failed surgeries, with 12‑month IOP reduction data guiding FDA plans.
By: Andrew Moshfeghi, Martin David Harp, Kassi Filkins
Seven-year Vestrum data: anti-VEGF gaps hit 40% of wet AMD patients by year one, worsening vision.
The annual Best Hospitals report from US News & World Report compares more than 4500 hospitals across 14 specialties and 22 procedures and conditions.
By: Martin David Harp
Wet AMD gains a new FDA-approved therapy as retina, glaucoma, and dry eye pipelines surge—plus AI, devices, and workforce trends reshaping care.
By: Martin David Harp
The trial is evaluating the company’s orally administered synthetic cannabinoid, ART27.13
By: Martin David Harp
AI model beats human graders at spotting glaucoma risk in UK population retinal photos, boosting accuracy and strengthening the case for scalable AI vision screening.
By: Martin David Harp
AI accelerates retina trials and imaging insights, boosts screening access, and raises urgent questions on regulation, privacy, and equity.
By: Martin David Harp
Large cohort links long-term tadalafil for urinary symptoms to modestly higher open-angle glaucoma risk.
By: Martin David Harp
A same-platform, prospective comparison of 123 eyes suggests diffractive trifocal optics don't compromise standard automated perimetry outside the central 5°
